Featured Research

from universities, journals, and other organizations

Innovative technique provides inexpensive, rapid, detailed analysis of proteins

Date:
March 24, 2014
Source:
Arizona State University
Summary:
The power of MSIA platform, with a vision towards clinical adoption has been demonstrated by scientists. The research reports a high-throughput method for quantifying and characterizing insulin-like growth factor 1, or IGF1, at a rate of >1,000 human samples a day. "From our knowledge, this is really the first viable option for routine analysis in a clinical laboratory that meets cost and time requirements while taking advantage of mass spectroscopy to quantify proteins," the lead author says.

This image shows Dr. Paul Oran, a researcher in the Biodesign Institute's Molecular Biomarkers Lab.
Credit: Anais Bon for the Biodesign Institute at Arizona State University

Proteins are vital participants in virtually all life processes, including growth, repair and signaling in cells; catalysis of chemical reactions and defense against infection. For these reasons, proteins can provide critical signposts of health and disease, provided they can be identified and assessed in a clinical setting.

Accurately characterizing proteins for diagnostic and therapeutic purposes has been an enormous challenge for the medical community. At the Biodesign Institute's Molecular Biomarkers Laboratory at Arizona State University, research focuses on the analysis of proteins using mass spectrometry (MS) -- a powerful tool for the detailed investigation of protein structure.

The facility is under the direction of Dr. Randy Nelson, a pioneer in the field and developer Mass Spectrometric Immunoassay (MSIA), a high-throughput protein quantification technique that also provides detailed protein information including post-translation modifications and genetic variants. Currently, the research group is focused on developing and translating new assays for protein biomarkers related to cancer, diabetes and heart disease.

In a new study appearing in the journal PLOS ONE, lead author Dr. Paul Oran and his colleagues demonstrate the power of the MSIA platform, with a vision towards clinical adoption. The research reports a high-throughput method for quantifying and characterizing insulin-like growth factor 1 (or IGF1) at a rate of >1,000 human samples a day. IGF1 is a critical protein implicated in human growth disorders as well as certain forms of cancer.

Insulin-like growth factor 1 is a 70-amino acid protein involved in cell growth, differentiation and transformation. Most IGF1 is secreted by the liver and acts as an endocrine hormone.

"For several decades, researchers have struggled to accurately quantify IGF1, an important molecule used to diagnose different kinds of growth disorders," Oran says.

In addition to providing a mass spectrometry-based IGF1 assay capable of being used clinically someday, the new research reports -- for the first time -- how efficient and cost-effective the technique can be. In their study, they were able to analyze over 1000 samples in a single day, (a milestone needed for eventual clinical use). "From our knowledge, this is the first demonstration of a MS-based targeted-proteomics assay for IGF1 -- or any protein for that matter -- capable of running at this speed and cost," says Dr. Oran.

Mass spectroscopy can readily identify genetic variants that are expressed on the protein level (for example Single-nucleotide polymorphisms). Such changes may alter or disable the function of the resulting protein. Further, mass spectroscopy can pinpoint changes that may occur to the protein after it has already been produced from the gene template -- so-called post-translational modifications.

The complex picture of multiple variants of a given gene coupled with post-translational protein alterations is referred to as microheterogeneity. Resulting protein variants play a major role in a variety of diseases, yet their identification has been fraught with difficulty. The current clinical standard for many types of protein quantification has been a method known as ELISA (for enzyme-linked immunosorbent assay).

Mass spectroscopy however is able to analyze critical protein variants wheras ELISAs can not. Microheterogeneity can also produce interference in ELISA tests, causing them to mechanically fail, yielding false readouts. Analysis through mass spectroscopy fixes the interference problem, additionally producing a rich portrait of protein information not available to ELISA. "As we and others have seen repeatedly, microheterogeneity is linked to many forms of disease," Oran says.

A mass spectrometer is an analytical instrument capable of producing spectra of the molecular masses of molecules contained in a sample. Once a sample is ready to be analyzed on a mass spectrometer, a protein and its variants can then be separated and categorized by their unique mass-to-charge ratio, which provides a sort of molecular fingerprint.

In the case under study in the current paper, IGF1 molecules detected in blood are usually bound with two other proteins. "To accurately quantify this molecule, we have to first disrupt this complex so we can get an accurate readout of total IGF1," Oran says.

The platform described in the current study is a so-called "top-down" approach to protein quantification. Instead of digesting the protein by means of proteases like trypsin and extracting the resulting tiny peptide fragments for analysis by mass spectroscopy ("bottom-up"), a top down method captures a full length protein and any protein variants in their entirety, enabling rapid analysis of a protein and its variants. "Other competing bottom-up approaches struggle to identify and thus ignore microheterogeneity, cost substantially more, and require more time and labor per sample," Oran says.

In the current study, the group quantified 1,054 human samples in 9 hours -- a throughput rate on a par with ELISA -- while providing more detailed information on the IGF1 protein, available only through mass spectroscopy. The new method also detected mutations in roughly 1 percent of the samples tested.

Future research will entail a larger validation study intended to support clinical adoption of the assay. The large universe of human proteins provides a broad range of plausible diagnostic targets. Several dozen assays using the technology have already been developed in Nelson's lab.

"From our knowledge, this is really the first viable option for routine analysis in a clinical laboratory that meets cost and time requirements while taking advantage of mass spectroscopy to quantify proteins," Oran says.


Story Source:

The above story is based on materials provided by Arizona State University. The original article was written by Richard Harth. Note: Materials may be edited for content and length.


Journal Reference:

  1. Paul E. Oran, Olgica Trenchevska, Dobrin Nedelkov, Chad R. Borges, Matthew R. Schaab, Douglas S. Rehder, Jason W. Jarvis, Nisha D. Sherma, Luhui Shen, Bryan Krastins, Mary F. Lopez, Dawn C. Schwenke, Peter D. Reaven, Randall W. Nelson. Parallel Workflow for High-Throughput (>1,000 Samples/Day) Quantitative Analysis of Human Insulin-Like Growth Factor 1 Using Mass Spectrometric Immunoassay. PLoS ONE, 2014; 9 (3): e92801 DOI: 10.1371/journal.pone.0092801

Cite This Page:

Arizona State University. "Innovative technique provides inexpensive, rapid, detailed analysis of proteins." ScienceDaily. ScienceDaily, 24 March 2014. <www.sciencedaily.com/releases/2014/03/140324181544.htm>.
Arizona State University. (2014, March 24). Innovative technique provides inexpensive, rapid, detailed analysis of proteins. ScienceDaily. Retrieved July 30, 2014 from www.sciencedaily.com/releases/2014/03/140324181544.htm
Arizona State University. "Innovative technique provides inexpensive, rapid, detailed analysis of proteins." ScienceDaily. www.sciencedaily.com/releases/2014/03/140324181544.htm (accessed July 30, 2014).

Share This




More Matter & Energy News

Wednesday, July 30, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Britain Testing Driverless Cars on Roadways

Britain Testing Driverless Cars on Roadways

AP (July 30, 2014) British officials said on Wednesday that driverless cars will be tested on roads in as many as three cities in a trial program set to begin in January. Officials said the tests will last up to three years. (July 30) Video provided by AP
Powered by NewsLook.com
China's Drone King Says the Revolution Depends on Regulators

China's Drone King Says the Revolution Depends on Regulators

Reuters - Business Video Online (July 30, 2014) Comparing his current crop of drones to early personal computers, DJI founder Frank Wang says the industry is poised for a growth surge - assuming regulators in more markets clear it for takeoff. Jon Gordon reports. Video provided by Reuters
Powered by NewsLook.com
3Doodler Bring 3-D Printing to Your Hand

3Doodler Bring 3-D Printing to Your Hand

AP (July 30, 2014) 3-D printing is a cool technology, but it's not exactly a hands-on way to make things. Enter the 3Doodler: the pen that turns you into the 3-D printer. AP technology writer Peter Svensson takes a closer look. (July 30) Video provided by AP
Powered by NewsLook.com
Climate Change Could Cost Billions, According To White House

Climate Change Could Cost Billions, According To White House

Newsy (July 29, 2014) A report from the White House warns not curbing greenhouse gas emissions could cost the U.S. billions. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins